Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
401. lappuse
... Calculate the clindamycin content as directed in paragraph ( g ) of this sec- tion . ( g ) Calculations . Calculate the clindamycin content of the sample as follows : Micrograms of clindamycin per milligram = where : X R1 xWsx f R1 x W ...
... Calculate the clindamycin content as directed in paragraph ( g ) of this sec- tion . ( g ) Calculations . Calculate the clindamycin content of the sample as follows : Micrograms of clindamycin per milligram = where : X R1 xWsx f R1 x W ...
403. lappuse
... Calculate the spectinomycin content as directed in paragraph ( f ) of this section . ( f ) Calculations . Calculate the spectinomycin content of the sample as follows : Micrograms of spectinomycin = per milligram R1 × W × ƒ И S R , W И ...
... Calculate the spectinomycin content as directed in paragraph ( f ) of this section . ( f ) Calculations . Calculate the spectinomycin content of the sample as follows : Micrograms of spectinomycin = per milligram R1 × W × ƒ И S R , W И ...
406. lappuse
... Calculations— ( i ) Percent anhydrotetracyclines . Calculate the per- cent anhydrotetracyclines as follows : Axbxc 20.28 where : A = Absorbance of the sample solution at 438 nanometers ; b = Volume of fraction in milliliters ; c ...
... Calculations— ( i ) Percent anhydrotetracyclines . Calculate the per- cent anhydrotetracyclines as follows : Axbxc 20.28 where : A = Absorbance of the sample solution at 438 nanometers ; b = Volume of fraction in milliliters ; c ...
413. lappuse
... Calculate the griseofulvin content as directed in paragraph ( f ) of this section . ( f ) Calculations . Calculate the griseo- fulvin content of the sample as follows : where : Micrograms of griseofulvin per milligram R1 × W × f S Rs ...
... Calculate the griseofulvin content as directed in paragraph ( f ) of this section . ( f ) Calculations . Calculate the griseo- fulvin content of the sample as follows : where : Micrograms of griseofulvin per milligram R1 × W × f S Rs ...
421. lappuse
... Calculations . Calculate the dactinomycin content as described in the individual monograph for the drug being tested . [ 49 FR 24017 , June 11 , 1984 , as amended at 50 FR 5749 , Feb. 12 , 1985 ] § 436.332 High - pressure ...
... Calculations . Calculate the dactinomycin content as described in the individual monograph for the drug being tested . [ 49 FR 24017 , June 11 , 1984 , as amended at 50 FR 5749 , Feb. 12 , 1985 ] § 436.332 High - pressure ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning